Longevity investment bulletin: Celmatix, BlueRock, TruDiagnostic and more

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

The latest longevity updates from our investment news desk. 

Celmatix unveils largest endometriosis study

Ovarian longevity company Celmatix announced findings from its long-term collaboration to decode the genetic basis of endometriosis, a condition that globally impacts 1 in 10 women. This is the largest study on endometriosis genetics conducted to date. Findings from the study demonstrate a shared genetic basis for endometriosis and other types of pain seemingly unrelated to endometriosis, including migraine, back pain and multi-site pain.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2075

BlueRock Therapeutics

Longevity level(s):

  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.
  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.

Overview

BlueRock Therapeutics is a clinical-stage cell therapy company developing regenerative medicines to address degenerative diseases across neurology, cardiology, ophthalmology, and immunology. The company leverages proprietary technology for manufacturing pluripotent stem cells at scale, combined with advanced gene editing capabilities to engineer therapeutic cells with enhanced function. BlueRock's approach targets fundamental cellular loss and dysfunction by replacing damaged or lost cells rather than managing symptoms, with lead programs in Parkinson's disease and inherited retinal diseases. As a wholly-owned subsidiary of Bayer AG, the company operates independently while benefiting from Bayer's resources and expertise in cell and gene therapy development.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

LT Staff

Longevity.Technology's in-house writing staff.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oyster surfaces with $60m and a tau degrader that travels light

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE